Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma

Phase 3VT3989Positive

AI Analysis

Summary

Vivace Therapeutics announces leadership strengthening and FDA approval to proceed with Phase 3 sTEADfast trial for VT3989, a first-in-class TEAD inhibitor for mesothelioma treatment.

Clinical Trial Data

Phase

Phase 3

Outcome Details

FDA grants Safe to Proceed for pivotal Phase 3 sTEADfast clinical study

Importance:7/10

Sentiment:

0.70

Phase 3TEAD inhibitorFDA approvalmesotheliomaleadership appointmentclinical trial

Related Companies

$INTI $DFPH $TRAX

Read the original article

Published by PR Newswire Clinical Trials on August 26, 2026 11:00 AM

Read Original